Notes / Company

Ipca Laboratories Ltd.

IPCALAB BSE 524494 ISIN INE571A01038 Pharmaceuticals

Fundamentals

Market cap: ₹41,049 cr
P/E: 35.97×
ROE: 10.62%
Debt / equity: 0.19
Div yield: 0.37%
52-week range: 1252.95 — 1679.45

Research on Tijori Finance

Company snapshot

Ipca Laboratories Ltd.

Pharmaceuticals

₹41,042 cr

P/E 35.97×

Latest quarter · Mar 2026

Sales₹2,388 cr

Net profit₹309 cr

Op. margin+20.3%

EPS₹11.79

Strength & growth

Debt / equity0.19×

Current ratio2.50×

Sales CAGR+13.1%

EPS CAGR+28.6%

The timeline — 1 note on Ipca Laboratories Ltd.

June 2026

12 Jun 26 · 5:28 PM IST Lead

Lead · Large cap

Ipca Labs lands global licence for subcutaneous biologics platform

The deal with Bhami's Research Laboratory gives Ipca worldwide rights to develop multiple monoclonal antibodies for oncology and inflammatory diseases, expanding its biosimilar pipeline into novel drug delivery.

Verify on exchange BSE filings for IPCALAB NSE filings for IPCALAB Tijori Finance company page